PCN87 Budget Impact Analysis (BIA) of Ruxolitinib for Treatment of Intermediate-2 or High Risk IPSS Myelofibrosis in the Brazilian Public Healthcare System (SUS)
Jun 1, 2021, 00:00
10.1016/j.jval.2021.04.179
https://www.valueinhealthjournal.com/article/S1098-3015(21)00396-X/fulltext
Title :
PCN87 Budget Impact Analysis (BIA) of Ruxolitinib for Treatment of Intermediate-2 or High Risk IPSS Myelofibrosis in the Brazilian Public Healthcare System (SUS)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00396-X&doi=10.1016/j.jval.2021.04.179
First page :
Section Title :
Open access? :
No
Section Order :
10757